I can't believe people invest in a stock without doing any research!
Dimerix is not a developer of new drugs. Their "product" is a discovery platform that identifies combinations of two existing drugs that can work in synergy to treat a particular medical condition better than each individual drug on its own. The first of these (DMX-200) is currently undergoing trials for kidney disease, and is a combination of two existing off-patent drugs (irbesartan and propagermanium) that have each been around for decades.
The next candidate will be DMX-700 for treatment of pulmonary heart disease. There are more candidates in the pipeline.
Hopefully DMX-200 will be approved so the revenue it generates can fund the development of this pipeline (and pay a healthy dividend to shareholders).
https://dimerix.com/technology/
DXB Chart, page-849
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.035(6.48%) |
Mkt cap ! $316.0M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 58.0¢ | 53.0¢ | $2.646M | 4.754M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
57.5¢ |
Change
0.035 ( 7.26 %) |
||||
| Open | High | Low | Volume | ||
| 53.0¢ | 58.0¢ | 52.5¢ | 2466717 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| DXB (ASX) Chart |